Warfarin is more than seven decades old, carries the stigma of its origins as a rat poison, and requires regular blood monitoring that newer drugs do not. Yet cardiologists continue to prescribe it — and in certain clinical situations, they insist on it. The reason is straightforward: for patients with mechanical heart valves, antiphospholipid syndrome, or advanced kidney disease, warfarin remains either the only proven option or the clearly superior one. No newer anticoagulant has managed to replace it in these roles, and some trials that attempted to do so were halted early because patients on the newer drugs fared worse.
For the millions of older adults living with atrial fibrillation, heart valve replacements, or clotting disorders — many of whom also face cognitive decline or dementia — the question of which blood thinner to use is not academic. It affects daily routines, caregiver responsibilities, drug interactions, and out-of-pocket costs. In 2023, warfarin was still the 116th most commonly prescribed medication in the United States, with over 5 million prescriptions filled. This article examines exactly where warfarin holds its ground, why switching isn’t always wise, and what caregivers and families managing brain health alongside cardiovascular risk need to understand. This piece also covers the practical advantages warfarin still offers — from its measurability and reversibility to its dramatically lower cost — along with the specific populations where newer drugs have failed, and what recent guidelines say about elderly and frail patients who are already stable on warfarin.
Table of Contents
- Why Do Cardiologists Still Prescribe Warfarin When Newer Blood Thinners Exist?
- Mechanical Heart Valves and Antiphospholipid Syndrome — Where Warfarin Has No Substitute
- Advanced Kidney Disease and the Patients DOACs Were Never Tested On
- The Cost Question — Four Dollars Versus Eight Hundred
- Reversibility and Measurability — Warfarin’s Underappreciated Clinical Advantages
- What the 2024 ESC Guidelines Say About Frail and Elderly Patients
- The Future of Warfarin in an Aging Population
- Conclusion
- Frequently Asked Questions
Why Do Cardiologists Still Prescribe Warfarin When Newer Blood Thinners Exist?
The short answer is that direct oral anticoagulants, or DOACs, such as apixaban (Eliquis) and rivaroxaban (Xarelto), simply do not work for every patient. Warfarin inhibits four clotting factors — II, VII, IX, and X — while each DOAC targets only a single factor in the coagulation cascade. That broader mechanism matters enormously when the thrombotic risk is high, as with mechanical heart valves. The PROACT Xa trial, which tested apixaban against warfarin in patients with mechanical aortic valves, recorded 14 thromboembolic strokes in the apixaban group compared to zero in the warfarin group. The trial was stopped early.
A similar fate befell the RE-ALIGN trial testing dabigatran (Pradaxa) in the same population. These were not marginal differences — they were alarming enough to end the studies. Since its FDA approval in 1954, warfarin was the only long-term oral anticoagulant available until dabigatran arrived in 2010. That 56-year monopoly means clinicians have an enormous body of evidence on warfarin’s behavior in virtually every patient population — something the newer drugs, tested in narrower trial populations, cannot yet match. Among atrial fibrillation patients specifically, warfarin use did decline from 52.4% in 2011 to 17.7% in 2020, while DOAC use climbed from 4.7% to 47.9%. But that shift was driven primarily by convenience and marketing, not by warfarin’s failure. In the conditions where warfarin is irreplaceable, no amount of DOAC promotion has changed prescribing behavior.
Mechanical Heart Valves and Antiphospholipid Syndrome — Where Warfarin Has No Substitute
For anyone with a mechanical heart valve, warfarin is not a preference — it is the only approved anticoagulant. Mechanical valves create turbulent blood flow and foreign surface contact that generates clotting risk through multiple pathways. Blocking a single clotting factor, as DOACs do, is simply not enough. The clinical trials confirmed this in the starkest possible terms: patients on DOACs had strokes; patients on warfarin did not. No cardiologist or cardiac surgeon will prescribe a DOAC for a mechanical valve patient today. Antiphospholipid syndrome, or APS, presents a similarly clear picture. APS is an autoimmune clotting disorder that can cause strokes, deep vein thrombosis, and pregnancy complications.
When researchers compared DOACs to warfarin in APS patients, the DOAC group experienced arterial events at a rate of 10.3% compared to 1.3% with warfarin. The stroke rate was 8.6% versus 0%. International guidelines now recommend warfarin for APS, especially in patients who test positive for all three antiphospholipid antibodies — so-called triple-positive APS. However, if a patient has only a single positive antibody and low overall thrombotic risk, some specialists may consider alternatives on a case-by-case basis. The point is that these decisions demand specialist involvement, not a blanket switch at the pharmacy counter. For caregivers and families managing dementia alongside one of these conditions, the implications are significant. A person with a mechanical valve and cognitive decline still needs warfarin — there is no safer substitute. That means INR monitoring, dietary consistency, and vigilant medication management must remain part of the care plan regardless of the added complexity dementia introduces.
Advanced Kidney Disease and the Patients DOACs Were Never Tested On
Chronic kidney disease is exceptionally common among older adults, and it frequently coexists with atrial fibrillation and cognitive impairment. Most DOACs are cleared through the kidneys, and the landmark trials that established their safety and efficacy excluded patients with advanced chronic kidney disease — stages 4 and 5, including those on dialysis. this leaves a significant gap. Only warfarin and apixaban carry FDA approval for use in patients with CKD or end-stage kidney disease, and warfarin remains the first-line choice in many end-stage renal disease patients. The practical consequence for dementia caregivers is real.
An older adult on dialysis who also has atrial fibrillation is likely on warfarin because the evidence base for DOACs simply does not cover their situation. Switching such a patient to a DOAC based on general atrial fibrillation guidelines would be inappropriate and potentially dangerous. If a loved one with kidney disease and cognitive decline is on warfarin, it is worth understanding that this may be the most evidence-supported option available — not an outdated holdover. However, warfarin in kidney disease patients does carry its own risks. Impaired kidney function can make INR levels less predictable, and the dietary restrictions and drug interactions that come with warfarin require more attentive management. For patients who cannot reliably communicate symptoms or manage their own medications — a common reality in moderate to advanced dementia — this means the caregiving team must be even more diligent about monitoring and communication with the prescribing physician.
The Cost Question — Four Dollars Versus Eight Hundred
The financial difference between warfarin and the newer anticoagulants is not subtle. Generic warfarin can cost as little as $4 per month. Brand-name Eliquis runs approximately $550 to $810 per month without insurance. Xarelto is around $820 per month without insurance. For older adults on fixed incomes, or for families already bearing the substantial costs of dementia care — which can exceed $50,000 annually for memory care facilities — this price gap is not trivial. The tradeoff, of course, is that warfarin requires regular INR blood testing, typically every two to four weeks, which adds its own costs and logistical burdens. For a person with dementia, getting to a lab or clinic for blood draws can be genuinely difficult.
Home INR testing kits exist but add expense and require someone capable of operating the device and interpreting the results. DOACs eliminate this monitoring requirement entirely, which is a legitimate advantage. But when a patient is already stable on warfarin with consistent INR values, the 2024 European Society of Cardiology guidelines suggest that the disruption of switching may not be worth it — particularly for frail patients over age 75 with multiple medications. The calculation is individual. A patient with good INR control, a reliable caregiver, and limited financial resources may be far better served staying on warfarin than switching to a DOAC that costs 100 to 200 times more per month. A patient with erratic INR values, no reliable monitoring support, and adequate insurance coverage may benefit from a DOAC. Neither answer is universally correct.
Reversibility and Measurability — Warfarin’s Underappreciated Clinical Advantages
One of warfarin’s oldest features turns out to be one of its most valuable in emergency situations: its effect is easily measured and easily reversed. The INR blood test tells a clinician exactly how anticoagulated a patient is at any given moment. No routine equivalent exists for DOACs. If a patient on warfarin falls and hits their head — a common and dangerous event in dementia — the emergency department can immediately check the INR and know the degree of bleeding risk. With a DOAC, the clinical picture is murkier. Reversal is similarly straightforward.
An oral dose of just 1 milligram of vitamin K can correct an INR of 4.0 to 10.0 within 24 hours. For true emergencies, prothrombin complex concentrates provide near-immediate reversal. While DOAC-specific reversal agents do exist — idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors — they are expensive, not universally available in smaller hospitals, and have their own limitations. For patients with dementia who are at elevated fall risk, the ability to quickly measure and reverse anticoagulation is a meaningful safety consideration. The warning here is that measurability only helps if someone is actually doing the measuring. A warfarin patient whose INR goes unchecked for months is at greater risk than a DOAC patient with no monitoring at all. The advantage of warfarin’s measurability depends entirely on a functioning care system around the patient — regular appointments, reliable transportation, and a caregiver or family member who tracks results and communicates with the medical team.
What the 2024 ESC Guidelines Say About Frail and Elderly Patients
The 2024 European Society of Cardiology guidelines addressed a question that many geriatricians and dementia care providers have been asking: should elderly, frail patients who are stable on warfarin be switched to a DOAC? The answer, in selected cases, is no. The guidelines state that frail patients aged 75 and older with polypharmacy who have stable, well-controlled INR values may reasonably remain on warfarin rather than undergo the risks and disruption of a medication switch.
This matters for dementia care because medication changes in cognitively impaired older adults carry their own dangers. New drugs mean new side effect profiles to watch for, new dosing schedules to learn, and a transition period during which anticoagulation may be suboptimal. For a patient with dementia who has been on warfarin for years with good results, the guideline endorsement of staying the course provides important clinical backing for what many caregivers already sense — that stability has its own value.
The Future of Warfarin in an Aging Population
Warfarin’s prescription numbers will likely continue to decline as DOAC use expands and as generic versions of apixaban and rivaroxaban eventually bring prices down. But warfarin will not disappear. Its irreplaceability in mechanical valve patients and APS guarantees ongoing use, and its cost advantage will persist in healthcare systems around the world where newer drugs remain unaffordable.
Research into better anticoagulation monitoring, including point-of-care INR devices and pharmacogenomic dosing, may also make warfarin easier to manage over time. For the dementia care community specifically, the conversation around anticoagulation deserves more nuance than “newer is better.” The right blood thinner for any individual depends on their specific diagnosis, kidney function, fall risk, financial situation, and the strength of the caregiving support around them. Warfarin, for all its age and inconvenience, remains the right answer for a meaningful number of patients — and understanding why helps families and caregivers advocate more effectively for the people in their care.
Conclusion
Warfarin’s place in modern cardiology is narrower than it once was, but it is firmly held. In mechanical heart valve patients, it is the only option. In antiphospholipid syndrome, it is dramatically superior to newer alternatives. In advanced kidney disease, it remains first-line when DOACs lack evidence. And in frail elderly patients who are already stable on it, recent guidelines support leaving well enough alone.
Its low cost, easy reversibility, and precise measurability are genuine clinical advantages that no DOAC currently matches across the board. For families navigating dementia care alongside cardiovascular disease, the key takeaway is that warfarin is not a sign of outdated medicine. If a loved one is on warfarin, there is very likely a specific, evidence-based reason. The priority should be ensuring that INR monitoring stays consistent, that the care team communicates clearly about results and dose adjustments, and that any proposed medication changes are discussed thoroughly with a cardiologist or hematologist who understands the full clinical picture. In a medical landscape that often equates new with better, warfarin is a reminder that sometimes the old tool is still the sharpest one in the kit.
Frequently Asked Questions
Is warfarin safe for someone with dementia who falls frequently?
Falls are a serious concern with any anticoagulant, not just warfarin. However, warfarin has an advantage in that its level of anticoagulation can be precisely measured with an INR test, and it can be reversed quickly with vitamin K or prothrombin complex concentrates. The decision to continue anticoagulation in a frequent faller should involve a careful risk-benefit discussion with the prescribing physician, weighing stroke risk against bleeding risk.
Why can’t my family member with a mechanical heart valve switch to Eliquis or Xarelto?
Clinical trials that tested DOACs in mechanical valve patients were stopped early because patients on the newer drugs experienced significantly more strokes and clotting events than those on warfarin. The PROACT Xa trial found 14 thromboembolic strokes in the apixaban group versus zero in the warfarin group. Warfarin remains the only approved anticoagulant for mechanical heart valves.
How often does someone on warfarin need blood tests?
Most patients on warfarin need INR testing every two to four weeks once their dose is stable. During initial dosing or after medication or dietary changes, testing may be needed more frequently. Home INR testing devices are available and can reduce the burden of clinic visits, which is particularly helpful for patients with dementia who find travel difficult.
Is it worth switching from warfarin to a DOAC just to avoid blood tests?
Not necessarily. The 2024 ESC guidelines specifically note that frail patients aged 75 and older who are stable on warfarin with well-controlled INR values may reasonably stay on warfarin. Medication switches in elderly patients with polypharmacy carry their own risks. The decision should be individualized based on INR stability, kidney function, cost considerations, and the patient’s overall clinical situation.
Is generic warfarin as effective as brand-name Coumadin?
Generic warfarin is considered therapeutically equivalent to brand-name Coumadin by the FDA. At roughly $4 per month compared to $550 to $820 per month for brand-name DOACs, the cost difference is substantial. Some clinicians prefer that patients stick with the same manufacturer’s generic to minimize minor variations in absorption, but this is a matter of clinical preference rather than a safety concern.
Does warfarin interact with dementia medications?
Warfarin has a long list of drug interactions, and some medications used in dementia care can affect INR levels. Any time a new medication is started or stopped, the prescribing team should be aware that the patient is on warfarin, and INR should be rechecked. This includes over-the-counter supplements and herbal products, which caregivers sometimes add without consulting a physician.
